Skip to main content
    E

    Evoke Pharma Inc (EVOK)

    Official site

    DRUG MANUFACTURERS - SPECIALTY & GENERIC

    $11.00
    +0.00 (+0.00%)

    Last updated: Dec 17, 2025 at 4:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    44%(16/36)
    Avg Surprise
    -18.52%
    Last 12 of 36 reported quarters
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Sep 25
    Reported Nov 10
    -$0.45-$0.45-$0.45 - -$0.450.00%In line1
    0
    1
    30d
    +52.1%
    Jun 25
    Reported Aug 14
    -$0.62-$0.30-$0.30 - -$0.30-106.67%Miss1
    0
    1
    30d
    +33.3%
    Mar 25
    Reported May 12
    -$0.51-$0.33-$0.33 - -$0.33-54.55%Miss1
    No revisions (30d)
    -200.0%
    Dec 24
    Reported Mar 12
    -$0.77-$0.63N/A-22.22%Miss---30.5%
    Sep 24
    Reported Nov 7
    -$0.94-$0.38-$0.38 - -$0.38-147.37%Miss1
    No revisions (30d)
    -84.3%
    Jun 24
    Reported Aug 8
    -$0.93-$0.72-$0.72 - -$0.72-29.08%Miss1
    No revisions (30d)
    -66.0%
    Mar 24
    Reported May 14
    -$0.17-$0.21-$0.21 - -$0.21+19.05%Beat1
    No revisions (30d)
    +74.6%
    Dec 23
    Reported Mar 14
    -$0.59-$0.50N/A-18.00%Miss---11.3%
    Sep 23
    Reported Nov 9
    -$0.51-$0.62-$0.62 - -$0.62+17.74%Beat1
    No revisions (30d)
    +15.0%
    Jun 23
    Reported Aug 10
    -$0.56-$0.73-$0.73 - -$0.73+23.29%Beat1
    No revisions (30d)
    +21.1%
    Mar 23
    Reported May 15
    -$0.67-$0.58-$0.58 - -$0.58-15.52%Miss1
    No revisions (30d)
    +20.2%
    Dec 22
    Reported Mar 21
    -$0.53-$0.53N/A0.00%In line--+26.4%

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    As of Nov 16, 2026, the price is 29.2% above its 50-day moving average. The 14-day RSI is 85.2, above 70, the overbought line.

    Moving Averages

    SMA 10$10.95
    SMA 20$10.88
    SMA 50$8.52
    SMA 200N/A
    EMA 10$10.94
    EMA 20$10.63
    EMA 50$9.11
    EMA 200$5.97

    MACD

    Line: 0.57Signal: 0.75Hist: -0.17

    ADX

    ADX: 73.1+DI: 50.4-DI: 5.5

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down32.0
    PSAR$10.40

    Bollinger Bands

    Upper Band$11.09
    Lower Band$10.67
    %B Position390%(Upper)
    Band Width0.79

    RSI (14-Day)

    Overbought
    85.2

    Momentum Oscillators

    Stoch %K96.6
    Stoch %D93.8
    Williams %RN/A
    ROC (10d)0.6%
    Momentum0.07
    CCI (20d)97.1
    MFI (14d)71.0

    Volatility Measures

    ATR (14d)$0.12(1.1%)
    StdDev (20d)0.11
    Hist Vol3.7%(Low)

    Volume Flow

    VWAP$11.00
    OBV148.4M
    AD Line-82.0M
    CMF (20d)0.002

    Volume Metrics

    Avg Vol (20d)27.3K
    Vol RatioN/A
    VWMA (20d)$10.87

    Pivot Points

    R3$11.03
    R2$11.01
    R1$11.01
    Pivot Point$10.99
    S1$10.99
    S2$10.97
    S3$10.97

    Advanced Oscillators

    TSI69.51
    Ultimate Osc59.4
    KST493.88

    Financial Performance

    Related GNG Research

    No research available

    Be the first to write about EVOK

    News

    No news available

    Company news will appear here when available

    Evoke Pharma Competitors

    Peers by sector and size for Evoke Pharma (EVOK) include Galecto, Rockwell Medical and Sangamo Therapeutics.

    Sector: Healthcare

    EVOK Bull Case vs Bear Case

    Bear case

    • EVOK beat EPS estimates in 12.5% of its last 8 reported quarters.

    EVOK Earnings: Beat Rate

    Beat rate
    1 of 8 quarters (12.5%)
    Average surprise
    -44.9%

    EVOK Earnings Call

    The latest EVOK earnings call transcript on file is labeled 2024Q4.

    Read the 2024Q4 transcript

    See insider activity

    Updated Nov 13, 2025. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.